DexCom, Inc. (NASDAQ:DXCM) EVP Chad Patterson sold 291 shares of the firm’s stock in a transaction that occurred on Thursday, September 9th. The stock was sold at an average price of $541.37, for a total transaction of $157,538.67. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of DexCom stock opened at $542.23 on Wednesday. The business has a fifty day simple moving average of $497.06 and a two-hundred day simple moving average of $421.02. DexCom, Inc. has a 1 year low of $305.63 and a 1 year high of $559.75. The company has a market capitalization of $52.46 billion, a price-to-earnings ratio of 103.28, a P/E/G ratio of 14.59 and a beta of 0.77. The company has a debt-to-equity ratio of 0.86, a current ratio of 5.78 and a quick ratio of 5.25.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 29th. The medical device company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.33. DexCom had a return on equity of 16.17% and a net margin of 24.45%. The business had revenue of $595.10 million during the quarter, compared to the consensus estimate of $548.02 million. As a group, equities analysts anticipate that DexCom, Inc. will post 2.46 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on DXCM shares. Piper Sandler raised their price target on shares of DexCom from $500.00 to $550.00 and gave the stock an “overweight” rating in a research note on Friday, July 30th. Raymond James raised their price target on shares of DexCom from $466.00 to $515.00 and gave the stock an “outperform” rating in a research note on Friday, July 30th. They noted that the move was a valuation call. Oppenheimer raised their price target on shares of DexCom from $500.00 to $525.00 and gave the stock an “outperform” rating in a research note on Friday, July 30th. Cowen decreased their target price on shares of DexCom from $540.00 to $525.00 and set an “outperform” rating for the company in a research note on Wednesday, July 21st. Finally, Barclays assumed coverage on shares of DexCom in a research note on Monday, May 24th. They issued an “overweight” rating and a $500.00 target price for the company. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $500.00.
DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.
Featured Story: Intrinsic Value
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.